These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 21892196)
1. A systematic review of the effects and mechanisms of preoperative 5α-reductase inhibitors on intraoperative haemorrhage during surgery for benign prostatic hyperplasia. Zong HT; Peng XX; Yang CC; Zhang Y Asian J Androl; 2011 Nov; 13(6):812-8. PubMed ID: 21892196 [TBL] [Abstract][Full Text] [Related]
2. Transurethral Resection of Prostate and Bleeding: A Prospective, Randomized, Double-Blind Placebo-Controlled Trial to See the Efficacy of Short-Term Use of Finasteride and Dutasteride on Operative Blood Loss and Prostatic Microvessel Density. Bansal A; Arora A J Endourol; 2017 Sep; 31(9):910-917. PubMed ID: 28650680 [TBL] [Abstract][Full Text] [Related]
3. Impact of preoperative 5α-reductase inhibitors on perioperative blood loss in patients with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. Zhu YP; Dai B; Zhang HL; Shi GH; Ye DW BMC Urol; 2015 Jun; 15():47. PubMed ID: 26032962 [TBL] [Abstract][Full Text] [Related]
4. The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis. Cindolo L; Fanizza C; Romero M; Pirozzi L; Autorino R; Berardinelli F; Schips L World J Urol; 2013 Jun; 31(3):665-71. PubMed ID: 23239103 [TBL] [Abstract][Full Text] [Related]
5. Effect of dutasteride on microvessel density in benign prostatic hyperplasia. Sugie S; Mukai S; Tsukino H; Iwamoto H; Kobayashi T; Toda Y; Kamoto T In Vivo; 2014; 28(3):355-9. PubMed ID: 24815838 [TBL] [Abstract][Full Text] [Related]
6. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029 [TBL] [Abstract][Full Text] [Related]
7. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Bartsch G; Rittmaster RS; Klocker H World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710 [TBL] [Abstract][Full Text] [Related]
8. A Systematic Review and Meta-Analysis of the Effects on Dutasteride Treatment for Reducing Surgical Blood Loss during Transurethral Resection of the Prostate. Ren J; Lai S; Jiang Z; Xu X; Diao T; Thiruchelvam N; Zhang G Urol Int; 2017; 98(4):456-465. PubMed ID: 28006778 [TBL] [Abstract][Full Text] [Related]
9. [Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia]. Arena F Minerva Urol Nefrol; 2013 Sep; 65(3):211-6. PubMed ID: 23872632 [TBL] [Abstract][Full Text] [Related]
10. Clinical effects and economical impact of dutasteride and finasteride therapy in Italian men with LUTS. Cindolo L; Berardinelli F; Fanizza C; Romero M; Pirozzi L; Tamburro FR; Pellegrini F; Neri F; Pitrelli A; Schips L Arch Ital Urol Androl; 2013 Dec; 85(4):200-6. PubMed ID: 24399122 [TBL] [Abstract][Full Text] [Related]
11. The effect of 5alpha-reductase inhibition with finasteride and dutasteride on bone mineral density in older men with benign prostatic hyperplasia. Mačukat IR; Spanjol J; Orlič ZC; Butorac MZ; Marinovič M; Ćupič DF Coll Antropol; 2014 Sep; 38(3):835-9. PubMed ID: 25420363 [TBL] [Abstract][Full Text] [Related]
12. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride. Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700 [TBL] [Abstract][Full Text] [Related]
13. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). Nickel JC; Gilling P; Tammela TL; Morrill B; Wilson TH; Rittmaster RS BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695 [TBL] [Abstract][Full Text] [Related]
14. Current status of 5alpha-reductase inhibitors in the treatment of benign hyperplasia of prostate. Kumar VL; Wahane VD Indian J Med Sci; 2008 Apr; 62(4):167-75. PubMed ID: 18445985 [TBL] [Abstract][Full Text] [Related]
15. Dutasteride: a potent dual inhibitor of 5-alpha-reductase for benign prostatic hyperplasia. Rabasseda X Drugs Today (Barc); 2004 Aug; 40(8):649-61. PubMed ID: 15510237 [TBL] [Abstract][Full Text] [Related]
16. 5α-reductase type 1 modulates insulin sensitivity in men. Upreti R; Hughes KA; Livingstone DE; Gray CD; Minns FC; Macfarlane DP; Marshall I; Stewart LH; Walker BR; Andrew R J Clin Endocrinol Metab; 2014 Aug; 99(8):E1397-406. PubMed ID: 24823464 [TBL] [Abstract][Full Text] [Related]
17. Is There a Role for Preoperative 5 Alpha Reductase Inhibitors in Reducing Prostate Vascularity and Blood Loss? Bruha M; Welliver C Curr Urol Rep; 2017 Oct; 18(10):75. PubMed ID: 28766115 [TBL] [Abstract][Full Text] [Related]
19. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908 [TBL] [Abstract][Full Text] [Related]
20. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. Andriole G; Bruchovsky N; Chung LW; Matsumoto AM; Rittmaster R; Roehrborn C; Russell D; Tindall D J Urol; 2004 Oct; 172(4 Pt 1):1399-403. PubMed ID: 15371854 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]